---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-21-000037"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2021-08-24T23:59:59+00:00"
generated_at: "2026-06-29T08:09:50.434453+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q1 FY22 revenue $7.99B (+23% reported), non-GAAP EPS $1.41, beats expectations; raises FY22 EPS guidance

## Summary
- Revenue $7.987B, up 23% reported and 19% organic; GAAP EPS $0.56, non-GAAP EPS $1.41.
- Cardiovascular revenue $2.89B (+15% organic); Medical Surgical $2.32B (+25% organic); Neuroscience $2.20B (+26% organic).
- Diabetes revenue $572M declined 3% organic; U.S. consumables and CGM sales fell mid-teens.
- FY22 organic revenue growth reiterated at ~9%; non-GAAP EPS guidance raised to $5.65-$5.75 from $5.60-$5.75.
- CEO Geoff Martha cites procedure recovery and share gains; company repurchasing shares and increasing R&D spend.

## SEC filing metadata
- accession: 0001613103-21-000037
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2021-08-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310321000037/0001613103-21-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310321000037/mdt-20210824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-21-000037
- JSON: https://secwatch.observer/filing/0001613103-21-000037.json
- Plain text: https://secwatch.observer/filing/0001613103-21-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.